220 related articles for article (PubMed ID: 26071134)
1. Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Qian K; Xu J; Wan H; Fu F; Lu J; Lin Z; Liu Z; Liu H
Gene; 2015 Sep; 569(2):173-81. PubMed ID: 26071134
[TBL] [Abstract][Full Text] [Related]
2. Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis.
Wang W; Ma H; Lu L; Sun G; Liu D; Zhou Y; Tong Y; Lu Z
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):419-30. PubMed ID: 26656901
[TBL] [Abstract][Full Text] [Related]
3. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
Orikaza CM; Morelli VM; Matos MF; Lourenço DM
Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
[TBL] [Abstract][Full Text] [Related]
4. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
5. Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes.
Huang Q; Feng D; Pan L; Wang H; Wu Y; Zhong B; Gong J; Lin H; Fei X
PeerJ; 2023; 11():e16352. PubMed ID: 38025709
[TBL] [Abstract][Full Text] [Related]
6. [Correlation analysis of thrombin-activatable fibrinolysis inhibitor single nucleotide polymorphism with venous thromboembolism].
Li C; Hou LH; Liu XE; Huang C; Wei XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):949-53. PubMed ID: 22931662
[TBL] [Abstract][Full Text] [Related]
7. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
Shi J; Zhi P; Chen J; Wu P; Tan S
Thromb Res; 2014 Sep; 134(3):610-6. PubMed ID: 25042727
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-Activatable Fibrinolysis Inhibitor Polymorphisms and Cerebral Venous Thrombosis in Mexican Mestizo Patients.
Arauz A; Argüelles N; Jara A; Guerrero J; Barboza MA
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1291-1296. PubMed ID: 29629564
[TBL] [Abstract][Full Text] [Related]
9. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.
Lichy C; Dong-Si T; Reuner K; Genius J; Rickmann H; Hampe T; Dolan T; Stoll F; Grau A
J Neurol; 2006 Mar; 253(3):316-20. PubMed ID: 16155788
[TBL] [Abstract][Full Text] [Related]
10. Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis.
Zwingerman N; Medina-Rivera A; Kassam I; Wilson MD; Morange PE; Trégouët DA; Gagnon F
PLoS One; 2017; 12(5):e0177768. PubMed ID: 28552956
[TBL] [Abstract][Full Text] [Related]
11. Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.
Zheng C; Li X; Kong C; Ke S; Peng C; Cui T; Gao M; Zhou Y; Guo W; Huang L; Petersen RB; Huang K
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):185-90. PubMed ID: 25396763
[TBL] [Abstract][Full Text] [Related]
12. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
de Bruijne EL; Gils A; Guimarães AH; Dippel DW; Deckers JW; van den Meiracker AH; Poldermans D; Rijken DC; Declerck PJ; de Maat MP; Leebeek FW
J Thromb Haemost; 2009 Jun; 7(6):919-27. PubMed ID: 19323787
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
14. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
Verdú J; Marco P; Benlloch S; Sanchez J; Lucas J
Thromb Haemost; 2006 Mar; 95(3):585-6. PubMed ID: 16525595
[No Abstract] [Full Text] [Related]
15. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Meltzer ME; Doggen CJ; de Groot PG; Meijers JC; Rosendaal FR; Lisman T
Haematologica; 2009 Jun; 94(6):811-8. PubMed ID: 19377074
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.
Fang P; Cai D; Du L; Shen F; Zhang C; Li M
Clin Appl Thromb Hemost; 2021; 27():10760296211029720. PubMed ID: 34189940
[TBL] [Abstract][Full Text] [Related]
17. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
Rattanawan C; Komanasin N; Settasatian N; Settasatian C; Kukongviriyapan U; Intharapetch P; Senthong V
Thromb Res; 2018 Nov; 171():171-176. PubMed ID: 30321704
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between leptin G-2548A polymorphisms and obesity risk: Evidence based on a meta-analysis.
Yan J; Wang X; Tao H; Yang W; Luo M; Lin F
Obes Res Clin Pract; 2015; 9(4):389-97. PubMed ID: 25733497
[TBL] [Abstract][Full Text] [Related]
19. The programmed cell death 1 gene polymorphisms (PD 1.3 G/A, PD 1.5 C/T and PD 1.9 C/T) and susceptibility to ankylosing spondylitis: a meta-analysis.
Yang M; Zou Y; Bai Y; Li M
J Orthop Sci; 2015 Jan; 20(1):55-63. PubMed ID: 25270018
[TBL] [Abstract][Full Text] [Related]
20. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
